Most Cancer Treatments Do Little to Help those Suffering with Mesothelioma, However Genetic Therapy May Be a Promising Alternative
Doctors who specialize in cancer treatment decide what course of treatment to go with with each patient. The options are endless. There is no one size fits all treatment option for malignant mesothelioma sufferers. This is due to the cancers high mortality rate, rareness, low treatment success rate, and small number of studies to provide meaningful statistics.
Mesothelioma patients have historically had a bleak outlook, but doctors have recently made progress. Traditional treatments for cancer are surgery (removing the tumor and surrounding tissue), radiation (killing the cancerous cells with radiation), and chemotherapy (poisoning the cancerous cells.) All three methods have problems. Mesothelioma patients treated with traditional radiation therapy have not responded well to it. In hopes to lessen damage to healthy tissue, researches are studying ways to aim radiation right at the tumor.
Surgery removes the mesothelial tissue around the tumor. This surgery is extensive and it is not clear how much the patient benefits. Common chemotherapy drugs that work on other types of cancer usually do not work on mesothelioma, and different mixtures of these drugs have not been successful. Similar to radiation, focus in research is focusing on treating the physical location of the tumor with emphasis on the pleural cavity.
The death rate for mesothelioma is so high that many of even the most sophisticated techniques in cancer treatment are tried out on patients. These techniques include a biologic therapy called the agent interleukin 2 and anti-angiogenesis drugs like thalidomide. The new drug pemetrexed (brand name Alimta) has shown good results in extending life with mesotheliomas..
Considered by oncologists is where the tumor is located, what stage the mesothelioma is in, and the age and health of the patient. Theres also photodynamic therapy and gene therapy ” two far-out new ways of attacking cancer. Patients afflicted with mesothelioma are benefitting in these clinical trials.
